Figure 1

Kaplan–Meier curve for clinical outcomes between very low-dose sacubitril/valsartan and standard dose group. Event-free survival of the composite-end point (cardiovascular death or heart failure rehospitalization) (Panel A) and heart failure (HF) rehospitalization (Panel B).